EGFR and neoplasm: Both of these mutations make the tumor more sensitive to compounds that inhibit EGFR, most likely by repositioning critical residues that surround the ATP-binding cleft of the tyrosine kinase domain of the receptor, which stabilizes interactions with both ATP and its competitive inhibitors [6], [7].